1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,820 | 8,060 | 14:40 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 27.03. | Selvita S.A.: Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 | 325 | PR Newswire | KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024... ► Artikel lesen | |
| 21.11.24 | Selvita Reports Significant Recovery in H2 2024, Sees Promising Outlook for the Future | 215 | PR Newswire | KRAKÓW, Poland, Nov. 21, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published... ► Artikel lesen | |
| 24.09.24 | Selvita S.A.: Selvita reports growing sales in Q2 and Q3, and projects increased profitability in H2 2024 | 463 | PR Newswire | KRAKÓW, Poland, Sept. 24, 2024 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading preclinical contract research organizations in Europe, has published its financial results for Q2 2024... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,500 | +0,27 % | QIAGEN N.V.: QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio | Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics CE-IVDR clearance granted for QIAstat-Dx... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - 8-K, Current Report | ||
| COSCIENS BIOPHARMA | 2,060 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 64,58 | -0,46 % | Halozyme Therapeutics, Inc.: Halozyme Raises 2025 Financial Guidance Ranges And Reports Strong Second Quarter 2025 Results | Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million
Net Income Increased 77% YOY to $165 million; Adjusted EBITDA... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ABCELLERA BIOLOGICS | 3,684 | -0,24 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| BIOMERIEUX | 114,50 | 0,00 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| GLOW LIFETECH | 0,026 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands MOD and .decimal brands in Saskatchewan Market, Advancing National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - September 16, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce the expansion of its MOD and .decimal... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 235,80 | -1,09 % | Disruption! Ab jetzt wird alles anders: BioNxt Solutions, BioNTech, Bio-Rad Laboratories | Der Ausbruch der Corona-Pandemie hat vieles verändert. Frei nach dem Motto "Einfach mal machen" setzten Unternehmen wie BioNTech auf die mRNA-Technologie. Der Erfolg inklusive Milliardenumsätzen folgte... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices Appoints Kenneth Bilenberg as CEO | ||
| BIOLINERX | 2,925 | -8,16 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,540 | -5,52 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals, Inc.: Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE in Chronic Rhinosinusitis (CRS) | Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10-million-patient marketAcquisition advances Paratek's vision... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,870 | -2,60 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results | FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
BURLINGTON, Mass., Aug. 14, 2025(Nasdaq:... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,347 | -1,95 % | Applied Therapeutics Reports Second Quarter 2025 Financial Results | - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE... ► Artikel lesen |
Das Unternehmen SELVITA SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,860 Euro und damit +1,03 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.